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Abstract
The increase in the number of medications used may result many negative
consequences for patients and health system. Elderly patients are more likely to
encounter these health problems associated with polypharmacy. Deprescribing, the
process of tapering, withdrawing, discontinuing, or stopping medications, is
important in reducing polypharmacy, adverse drug effects, inappropriate or inef-
fective medication use, and costs. Deprescribing in elderly patients in accordance
with the evidence based guidelines has many positive outcomes in older people such
as decrease in the risk of falls, improvement in cognition, and improvement in
patients’ global health status. Therefore, each visit of an elderly patient should be
considered as an opportunity to evaluate the unnecessary use or harms of the
prescribed or nonprescribed medications. Clinicians should decide to deprescription
process by individualized care goals in line with current guidelines. Beers Criteria,
STOPP/START and The Medication Appropriateness Index-MAI can be used to
assit clinicians to identify unnecessary or potentially inappropriate drugs and
reduce the number of medications in older patients. But, a balance is required
between over and under prescribing. In conclusion, prevention of polypharmacy
and withdrawing unneccesary and inappropriate medications may be the best clin-
ical decision for family physicians who follow the elderly in primary care.
Keywords: polypharmacy, deprescription, elderly, older adults, aging, drug use,
advers drug events, primary care
1. Introduction
Although lacking a consensus definition, the concurrent use of two or more
medications is described polypharmacy [1]. However, in many researches investi-
gating the use of multiple medications and their effects, the concurrent use of 5 or
more drugs is defined as “polypharmacy” [2–4]. The concurrent use of 2 or 3
medications does not cause a significant problem if they are chosen correctly, but
the use of 4 or more medications carries a significant risk. Although polypharmacy
is seen in all age groups, it is more common with increasing age. Nearly half of the
older people use at least 1 drug even though it is not necessary [5, 6]. One of the
most important causes for the increase in the number of medications used in the
elderly is the coexistence of more than one chronic disease.
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2. Polypharmacy in elderly
Increase in the number of medications used may cause many health problems.
As the metabolism and elimination of drugs will be affected by the decrease in
kidney and liver functions with increasing age, the older people are more suscepti-
ble to the negative effects of polypharmacy. In addition, with increasing age, the
onset of amnesia, decreased visual acuity, and the onset of physical disabilities cause
the elderly, who already use many drugs, to make mistakes in the use of drugs. As a
result, the elderly are more likely to encounter many health problems caused by the
use of multiple drugs. Therefore, polypharmacy is accepted as one of the geriatric
syndromes.
Apart from increasing age and the presence of chronic disease, other risk factors
for polypharmacy are listed below [7, 8]:
• Follow-up of patients by more than one physician and lack of communication
between physicians
• Patients’ drug expectations for their illness
• Medical guidelines specific to diseases, not to patients
• Pharmaceutical advertisements
• Recent hospitalization
• Over-the-counter drug sales
• Prescribing medication for symptoms rather than diagnosis
• Failure to adequately explain the medication changes to the patients by the
doctors
• Residing in long-term care facilities
• Prescription cascade (addition of new medications to counter adverse drug
reactions or drug side effects. For example, addition of an antitussive agent to
relieve cough caused by angiotensin converting enzyme inhibitors, or addition
of an antihypertensive due to increased blood pressure with NSAID use.
The increase in the number of medications used may result many negative
consequences for patients and health system. For example, overall, 30% of hospital
admissions are related in some way to medications in people aged over 65 years and
half of these could be prevented [9]. Also, with increasing age, compliance to drug
usage declines due to increase in the number of the drugs used, the beginning of
memory loss, weakness of vision and the onset of physical incapabilities. The most
common health problems reported in the elderly people associated with
polypharmacy are listed below [10–15]:
• Increase risk of:
◦ Drug interactions
◦ Advers drug events
2
Primary Care
◦ Morbidity and mortality
◦ Physical and cognitive dysfunction
◦ Falls and associated harms (hip fracture, etc)
◦ Prescribing cascade
• Increase in use of the health care system and hospitalizations
• Decreased compliance to medication use
• Increased treatment cost
• Increased need of residing in long-term care facilities
As can be seen above, most of the problems caused by polypharmacy can be
prevented. Visits for prescribing the medications used regularly, health maintanece
and control visits are the convenient opportunities for physicians to evaluate drug
interactions. In addition, while making a differential diagnosis for a new complaint
or symptom, polypharmacy and drug interactions, should be evaluated and kept in
mind that changes in the patient’s condition may be associated with drug interac-
tions or an adverse effect of a medication.
Although polypharmacy is referred to prescribed medications, the number of
over-the-counter and herbal/dietary supplements used should be also considered. It
should be noted that beside the all medications used by the patient, over-the-counter
drugs with dietary or herbal supplements should be evaluated in terms of interac-
tions. For example, garlic or Ginkgo biloba extract taken with warfarin may cause an
increased risk of bleeding. St. John’s wort taken with atorvastatin or diltiazem, may
increase the advers effects of atorvastatin or diltiazem in older adults [16, 17].
Even not recommended by a physician, elderly people self-medicate more than
the other age groups. This leads to an increased risk of adverse events and side
effects. For example, the use of non-steroidal anti-inflammatory drugs, which are
used common nonprescription, may lead to hypertension, decreased effect of the
antihypertensives or a gastrointestinal bleeding.
There are many web-based applications developed for the physicians to control
drug interactions. The addresses of some free applications that can be easily used on







Probably most of the medications used by the patients were prescribed and
clinically indicated. However, some medications may be unnecessary or cause harm
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over time due to physiological changes occur with aging or added health problems.
These physiological changes that occur with aging affect the sensitivity of drugs
mainly by causing changes in the pharmacokinetics of the drug. Pharmacodynamic
changes also play a role, although to a lesser extent. The changes in the number and
sensitivity of the receptors due to aging or some diseases that occur with aging, and
the change of post-receptor events are the main reasons for the changes in pharma-
codynamic responses of the medications. In general, these changes cause the effect
of the drug to occur more or less and the emergence of drug toxicity and adverse
drug reactions. Because of all these changes, the beneficial effects of drug use and
the potential harmful effects of drug use should be evaluated together. The decrease
in body functions, which occurs with aging is not the same in people of the same
age. Therefore, the concept of “patient centered assessment” becomes even more
important in the older age groups. Avoiding over-prescription and inappropriate
drugs in elderly patients is the other important point in preventing adverse health
problems caused by polypharmacy and changes due to aging. There are a few tools
can be used to assit clinicians to identify unnecessary or potentially inappropriate
drugs for older patients. Beers Criteria, Screening Tool of Older Person’s Potentially
Inappropriate Prescriptions (STOPP), Screening Tool to Alert to Right Treatment
(START) and The Medication Appropriateness Index-MAI are some of them
[18–20]. These tools allow the comparison of the patient’s medications in terms of
duplications, interactions, and potencially inappropriateness and to check for med-
ication adjustments required for certain disease states, such as renal impairment.
Another problem encountered with the polypharmacy in the elderly is the use of
narrow therapeutic index drugs. As a result of interaction of these drugs with other
drugs the therapeutic dose can be easily increased to the toxic dose due to reduction
in metabolism, increase in absorption or decrease in elimination. So, the medica-
tions with narrow therapeutic index may cause death even use in therapeutic doses.
Small changes in the dosage of narrow therapeutic index drugs can lead to signifi-
cant changes in pharmacodynamic response, particularly in elderly patients with
comorbidities or using multiple medications. Therefore, recognizing the narrow
therapeutic index drugs is very important issue in terms of preventing serious
problems. Narrow therapeutic index drugs commonly used are shown in Table 1.
In the light of these information, each visit of an elderly patient should be
considered as an opportunity to evaluate the unnecessary use or harms of the
prescribed or nonprescribed medications. Studies showed that reducing the number
of medications has many positive outcomes in older people such as decrease in the















Common narrow therapeutic ındex drugs.
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status [21–23]. Moreover, approxymately, over half of the people over 70 years of
age medicines could be discontinued [24].
In some cases, it is necessary to use multiple drugs for therapeutic purposes at
once. For example, concomitant use of aspirin, beta-blockers, ACE inhibitors and
lipid-lowering drugs is inevitable in cardiovascular diseases. For this reason, what
needs to be done is to try to keep the number of drugs as few as possible by making
a risk–benefit assessment by considering the personal treatment goals [25, 26].
In addition to the unnecessary and excessive use of drugs in the elderly, another
important problem is that some drugs are not prescribed by physicians or are not
used by patients, even though they are necessary. For example, it has been reported
that only half of the patients take an anticoagulant in atrial fibrillation, although the
guidelines suggest. It has also been reported that inhaled anticholinergic broncho-
dilators in COPD, SSRIs in depression, ACE inhibitors in the presence of diabetes
mellitus and hypertension are not prescribed although necessary [27]. The other
medications that are often underprescribed in the elderly include those used to
Alzheimer disease, pain (eg, opioids), heart failure, post-MI (β-blockers), glau-
coma, and incontinence. In addition to the medications, vaccines are not prescribed
as recommended.
3. Deprescription process
Deprescribing, the process of tapering, withdrawing, discontinuing, or stopping
medications, is important in reducing polypharmacy, adverse drug effects, inap-
propriate or ineffective medication use, and costs [28]. The first step in
deprescription is the identifing the patients with risk. To identifying the patients
with risk, a comprehensive geriatric assessment should be necessery. Comprehen-
sive geriatric assessment is a systematic evaluation of older people by a multidis-
ciplinary health professionals to determine the medical, psychological and
functional capabilities and develop a coordinated and integrated personalized fol-
low up plan. Comprehensive geriatric assessment of the elderly patient in primary
care should include multimorbidity, cognitive changes, functional status changes,
frailty, risk of falling, medication nonadherence, polypharmacy, transitions in care
setting, unexplained weight loss, and family concerns for safety [29]. Although
comprehensive geriatric assessment expected to be performed by a multidis-
ciplinary health professionals, family physicians have a central role in comprehen-
sive geriatric assessment and coordinating the care. Comprehensive geriatric
assessment can be performed in over time with regularly scheduled visits in pri-
mary care. During each visit, it should be targeted at least one domain and evalua-
tion of polypharmacy risk and polypharmacy related problems prioritized. Periodic
evaluation of a patient’s drug regimen and risk of polypharmacy and adverse drug
events is an essential component of comprehensive geriatric assessment. Patients
need to be specifically told to bring all of the over-the-counter products, ointments,
vitamins, ophthalmic preparations, or herbal medicines, used by them to the visit.
It should be aimed to reduce the number of drugs, particularly in those use 7 or
more drugs, a history of adverse drug reactions or falls, develope confusion or
lethargy as a new symptom, worsen general health status, transfered to nursing
homes, have multiple care providers or cared by more than one institutions. Antic-
ipation of polypharmacy and inappropriate drug use is a part of deprescription
process. Approximately one-fifth of the drugs used in elderly people are inappro-
priate drugs [30].
To reduce the number of medications used in older patients, Beers Criteria,
Screening Tool of Older Person’s Potentially Inappropriate Prescriptions (STOPP),
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Screening Tool to Alert to Right Treatment (START) and The Medication
Appropriateness Index-MAI can be used by the physicians [18–20]. The STOPP/
START guideline contributes to the recognition of potentially inappropriate
drugs for use in elderly patients and to drug selection in common diseases with
evidence-based recommendations. The Beers Criteria is a guide to identify the
inappropriate drugs that should be avoided in the elderly. The criteria include
three categories: those that should always be avoided (regardless of disease or
condition (eg, diphenhidramine, benzodiazepines); those that are potentially
inappropriate in older adults with particular health conditions or syndromes;
and those that should be used with caution (eg, carbamazepines, SSRIs) [19].
Medical Appropriateness Index, contributes to the evaluation of each medications
in terms of indication, efficacy, appropriate dose and correct use, drug interactions,
presence of medications with similar effect, appropriate treatment duration and
cost [20].
It can be predicted that polypharmacy and unnecessary drugs may be used by
the patients recently discharged from the hospital. It is known that medications
used temporarily during hospitalization are also continued to use after discharge by
the patients. Therefore, after discharge from the hospital, medications used by the
patients should be reviewed. Additionally, increasing age, female gender, higher
levels of education, cognitive dysfunction, general poor health, having cardiovas-
cular disease, hypertension, asthma, diabetes or using high-risk drugs
(antithrombotic agents, insulin, oral hypoglycaemic agents, cardiovascular and
central nervous system drugs, anticolinergics) are the risks for polypharmacy and
adverse drug events.
After the risk identification, the physician should prepare the patient and their
closers to deprescribing. Asking the elderly and caregivers, which medications they
prefer to use, and getting their opinion will make it easier for the physician. Because
the passion of the elderly to some drugs can be an obstacle in the process of
deprescribing, and the insistent attitude of the physician to discontinue the drug
may reduce the trust to the doctor. Moreover, learning the patients’ and caregivers’
preferences are the first step of shared decision making process, that be very
important in patient centered approachment in primary care.
Prioritization of the medicines to cease or doses to reduce is the second step of
deprescription [31, 32]. For this, it should be checked the medications in terms of
there is still a valid indication and benefit, presence of adverse drug reactions or
new symptoms and risky drugs eg. anticholinergic and sedating drugs.
If there is a medication that is not preferred by the patient among the medica-
tions considered for discontinuation, deprescription can be started by discontinuing
this medication.
If any adverse drug reaction or new symptom are suspected, the suspected drug
should be discontinued first, and the next target medication to discotinue should be
anticholinergic and sadative drugs. Because elderly patients are particularly suscep-
tible of anticholinergic and sedating drugs advers effects. Adverse effects associated
with anticholinergic use in older adults include memory impairment, confusion,
hallucinations, dry mouth, blurred vision, constipation, nausea, urinary retention,
impaired sweating, and tachycardia [33, 34]. Moreover, it was reported an associa-
tion between anticholinergic use and risk of community acquired pneumonia [35].
Presence of these symptoms should be a warning to the physician. Some examples
of anticholinergic drugs are shown in Table 2.
Discontinuation of the drugs with similar effects is another step in reducing the
number of drugs. Then, the presence of drugs that can be used in combination
among the drugs used should be reviewed, and if possible, the number of drugs
should be reduced by prescribing the medications in combination.
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Physicians should assess whether treatment goals have changed for the patient at
each visit. In updated guidelines, treatment goals may change based on new evi-
dence or depending on the patient’s age or other intervening disease. For example,
after recognizing that strict targeting for hemoglobin A1c and blood pressure values
was harmful in the elderly, the guidelines were updated on this issue [36, 37]. In
addition to goals of care, the patients’ life expectancy also considered in
deprescription process. The patient’s life expectancy may have been decrease by an
intervening cancer or other serious illness. In this case, some medications that are
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Clinicians should decide to discontinuation process by individualized treatment
goals in line with current guidelines.
It is known that non-pharmacological treatments are even more effective than
drug treatment in several chronic diseases. Therefore, while prescribing, non-
pharmacologic treatment options should always be considered first [26]. If the
patient can apply non-pharmacologic options, it will be easier to reduce the number
of drugs. For example, in many patients, hypertension can be controlled only by
sodium restriction or weight loss. In diabetes mellitus patients the number and dose
of the medications can be reduced by low glycemic index diet and exercise.
The steps of deprescription process was shown in Table 3.
If it is not possible to cease of medications, it should be considered whether it is
possible to reduce their dose. Because, many adverse drug reactions are dose-
related. While prescribing it is important to use the minimal dose required to obtain
clinical benefit.
3.1 Points to consider when reducing the number of medications
• A comprehensive geriatric assessment should be necessery to detect the risk of
polypharmacy, polypharmacy related problems, possibility to reduce the
number of medications and anticipate the consequences of withdrawal.
Although consern of withdrawal reactions may be a barrier to deprescription,
withdrawal reactions are seen rare when discontinuation is carried slowly and
carefully [38].
• While reducing the number of drugs, it is very important that some drugs
should be discontinued by tapering over time. Anticonvulsants,
benzodiazepines, corticosteroids, antidepressants, beta blockers, levodopa,
opiates, proton pump inhibitors, and gabapentin are the examples of drugs that
should not be stopped abruptly. Abrupt discontinuation of these drugs may
cause withdrawal syndrome and a rebound effect.
• Only stop or reduce one medicine at a time.
• Possible problems that may occur in case of discontinuation of the drug should
be anticipated.
• Drug interactions should also be considered while reducing the number of
drugs. For example, when using warfarin with omeprazole, discontinuation of
• Risk identification and anticipation
• Defining inappropriate or unnecessary medicine use
• Preparation of patient and their closers to deprescription
• Learning patient and caregivers preferences
• Prioritization of the medicines to cease or doses to reduce
• Checking valid indication and benefit of the medications
• Checking adverse drug reactions or new symptoms
• Identification anticholinergic and sedating drug use
• Identification of medications with similar effects
• Reviewing the presence of drugs that can be used in combination
• Assessing whether treatment goals have changed
• Considering non-pharmacologic options
Table 3.
The steps of deprescription.
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omeprazole, the INR may decrease because omeprazole had been inhibiting the
metabolism of warfarin.
• In cases where it cannot be decided which medication should be discontinued,
a collaboration with other physicians following the patient should be
established.
• The necessity of drug discontinuation should be explained to the patient and
their closers with an appropriate communication language.
• Effort should be made to improve communication in transition of the patients
between health care centers or caregivers. Sharing the medication lists used by
the patients or planned to withdrawal, between health providers at the time of
care transition may be help to prevent adverse drug events.
• After the drug is withdrawal, warning messages about the discontinuation of
the medications should be given to the patients in writing, a follow-up
appointment should be planned, and should be informed about when to
consult a doctor [39].
• Patients and their closers should be informed about the monitoring of blood
parameters that may change after drug withdrawal.
• While trying to prevent polypharmacy and polypharmacy-related problems in
elderly patients and to reduce unnecessary and inappropriate drug use, care
should be taken not to discontinue the drugs that the patient really needs.
START criteria is developed to help the identify potential prescribing
omissions in older patients can be used in this regard [18].
• If treatment is indicated, the current regimen with a higher probability of
adverse effects can be replaced with a safer alternative medication. As an
example, acetaminophen instead of NSAID.
4. Conclusion
The patient’s condition and goals of care changed over time are the key princi-
ples to be considered in deprescription. A comprehensive geriatric assessment
should be necessery to detect the risk of polypharmacy, polypharmacy related
problems, possibility to reduce the number of medications and anticipate the con-
sequences of withdrawal. Avoiding from over-prescribing and inappropriate medi-
cations in older patients is the key step to prevent negative health problems due to
polypharmacy. It should be kept in mind that in addition to over-prescribing,
under-prescribing appropriate medications is also of concern in older patients.
Therefore, a balance is required between over- and under-prescribing.
It should be kept in mind that reducing the number of drugs in the elderly
patients in accordance with the evidence based guidelines can be carried without
any serious problems and this situation can improve the health parameters of the
older patients. In conclusion, prevention of polypharmacy and withdrawing
unneccesary and inappropriate medications may be the best clinical decision in
older patients.
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